ORLANDO (MedPage Today) -- Giving a novel antiplatelet, vorapaxar, to acute coronary syndrome patients did not reduce mortality or serious cardiovascular events, but it did significantly increase the risk of major bleeding, including intracranial hemorrhage, researchers said here.
No comments:
Post a Comment